Amgen Inc. (AMGN) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
AMGN Insider Trading Activity
AMGN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $24,068,850 | 9 | 100 |
Related Transactions
| Busch Matthew C. | VP, Finance & CAO | 0 | $0 | 1 | $279,690 | $-279,690 |
| Grygiel Nancy A. | SVP & CCO | 0 | $0 | 1 | $483,808 | $-483,808 |
| Miller Derek | SVP, Human Resources | 0 | $0 | 2 | $593,934 | $-593,934 |
| Santos Esteban | EVP, Operations | 0 | $0 | 1 | $2.55M | $-2.55M |
| Gordon Murdo | EVP, Global Commercial Ops | 0 | $0 | 1 | $2.59M | $-2.59M |
| Graham Jonathan P | EVP & Gen. Counsel & Secy. | 0 | $0 | 1 | $7.34M | $-7.34M |
| REESE DAVID M | EVP & Chief Technology Officer | 0 | $0 | 2 | $10.23M | $-10.23M |
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Insider Activity of Amgen Inc.
Over the last 12 months, insiders at Amgen Inc. have bought $0 and sold $24.07M worth of Amgen Inc. stock.
On average, over the past 5 years, insiders at Amgen Inc. have bought $0 and sold $9.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,020 shares for transaction amount of $1M was made by Hassan Fred (director) on 2015‑08‑19.
List of Insider Buy and Sell Transactions, Amgen Inc.
| 2025-05-02 | Sale | Busch Matthew C. | VP, Finance & CAO | 1,000 0.0002% | $279.69 | $279,690 | -2.21% | |
| 2025-02-21 | Sale | REESE DAVID M | EVP & Chief Technology Officer | 25,225 0.0048% | $304.44 | $7.68M | -2.54% | |
| 2025-02-19 | Sale | Santos Esteban | EVP, Operations | 8,711 0.0016% | $292.84 | $2.55M | +1.24% | |
| 2025-02-19 | Sale | REESE DAVID M | EVP & Chief Technology Officer | 8,711 0.0016% | $293.22 | $2.55M | +1.24% | |
| 2025-02-19 | Sale | Miller Derek | SVP, Human Resources | 1,524 0.0003% | $293.74 | $447,655 | +1.24% | |
| 2025-02-18 | Sale | Miller Derek | SVP, Human Resources | 500 <0.0001% | $292.56 | $146,279 | +1.30% | |
| 2025-02-11 | Sale | Gordon Murdo | EVP, Global Commercial Ops | 8,771 0.0016% | $294.79 | $2.59M | +0.07% | |
| 2025-02-07 | Sale | Graham Jonathan P | EVP & Gen. Counsel & Secy. | 25,045 0.0046% | $293.12 | $7.34M | +1.08% | |
| 2025-02-05 | Sale | Grygiel Nancy A. | SVP & CCO | 1,589 0.0003% | $304.47 | $483,808 | -3.60% | |
| 2024-05-03 | Sale | Grygiel Nancy A. | SVP & CCO | 2,117 0.0004% | $313.09 | $662,802 | +1.20% | |
| 2023-12-04 | Sale | Grygiel Nancy A. | SVP & CCO | 2,096 0.0004% | $273.03 | $572,276 | +13.93% | |
| 2023-11-08 | Sale | Graham Jonathan P | EVP, Gen. Counsel & Secy. | 10,000 0.0019% | $272.81 | $2.73M | +14.49% | |
| 2023-08-10 | Sale | Gordon Murdo | EVP, Global Commercial Ops | 9,558 0.0018% | $262.43 | $2.51M | +8.82% | |
| 2022-11-09 | Sale | Khosla Rachna | SVP, Business Development | 387 <0.0001% | $292.90 | $113,352 | -12.01% | |
| 2022-11-08 | Sale | Grygiel Nancy A. | SVP & CCO | 545 0.0001% | $293.54 | $159,977 | -12.84% | |
| 2022-08-22 | Sale | Williams R Sanders | 200 <0.0001% | $249.96 | $49,992 | -1.12% | ||
| 2022-08-18 | Sale | ECKERT ROBERT | 6,600 0.0012% | $249.00 | $1.64M | -2.23% | ||
| 2022-05-23 | Sale | Williams R Sanders | 1,200 0.0002% | $250.00 | $300,000 | -0.65% | ||
| 2022-05-10 | Sale | Graham Jonathan P | EVP, Gen. Counsel & Secy. | 27,000 0.0051% | $241.81 | $6.53M | +3.63% | |
| 2021-05-12 | Sale | SUGAR RONALD D | director | 2,000 0.0002% | $161.12 | $322,230 | -6.81% |
Insider Historical Profitability
| Santos Esteban | EVP, Operations | 71546 0.0133% | $19.49M | 0 | 1 | |
| Gordon Murdo | EVP, Global Commercial Ops | 44186 0.0082% | $12.04M | 0 | 2 | |
| REESE DAVID M | EVP & Chief Technology Officer | 36922 0.0069% | $10.06M | 0 | 2 | |
| Graham Jonathan P | EVP & Gen. Counsel & Secy. | 28987 0.0054% | $7.9M | 0 | 5 | |
| Miller Derek | SVP, Human Resources | 8544 0.0016% | $2.33M | 0 | 2 | |
| Grygiel Nancy A. | SVP & CCO | 7210 0.0013% | $1.96M | 0 | 5 | |
| Busch Matthew C. | VP, Finance & CAO | 4034 0.0008% | $1.1M | 0 | 1 | |
| JOHNSON FRANKLIN P JR | director | 1636961 0.3044% | $445.92M | 0 | 15 | |
| Bradway Robert A | Chairman, CEO and President | 383102 0.0712% | $104.36M | 1 | 2 | +39.22% |
| FRITZKY EDWARD V | director | 231000 0.043% | $62.93M | 0 | 8 | |
| PERLMUTTER ROGER M | EVP, Research & Development | 186031 0.0346% | $50.68M | 0 | 6 | |
| OMENN GILBERT S | director | 176783 0.0329% | $48.16M | 0 | 7 | |
| LAZARUS STEVEN | director | 149343 0.0278% | $40.68M | 0 | 5 | |
| FENTON DENNIS M | Executive V.P., Operations | 117518 0.0219% | $32.01M | 0 | 20 | |
| MORROW GEORGE J | Exe VP, Global Commercial Ops | 93719 0.0174% | $25.53M | 1 | 4 | <0.0001% |
| ODRE STEVEN M | Sr. VP, Gen. Counsel & Secy. | 76705 0.0143% | $20.9M | 0 | 2 | |
| SCOTT DAVID J | SVP, Gen. Counsel & Secy. | 65558 0.0122% | $17.86M | 0 | 4 | |
| Harper Sean E | EVP, Research & Development | 56082 0.0104% | $15.28M | 0 | 15 | |
| Balachandran Madhavan | EVP, Operations | 55996 0.0104% | $15.25M | 0 | 4 | |
| MCNAMEE BRIAN M | EVP | 54643 0.0102% | $14.89M | 0 | 19 | |
| Meline David W | EVP & CFO | 49378 0.0092% | $13.45M | 0 | 1 | |
| CHOATE JERRY D | director | 48575 0.009% | $13.23M | 1 | 2 | <0.0001% |
| BONANNI FABRIZIO | EVP, Operations | 48491 0.009% | $13.21M | 0 | 13 | |
| Flanagan Thomas James | Sr VP & CIO | 41826 0.0078% | $11.39M | 0 | 4 | |
| Michael A Kelly | Acting CFO | 41041 0.0076% | $11.18M | 0 | 6 | |
| Piacquad David | SVP, Business Development | 39700 0.0074% | $10.81M | 0 | 1 | |
| BEIER DAVID W | SVP, Global Govt Affairs | 35612 0.0066% | $9.7M | 0 | 7 | |
| BALTIMORE DAVID | director | 31159 0.0058% | $8.49M | 0 | 8 | |
| BIONDI FRANK | director | 29780 0.0055% | $8.11M | 0 | 4 | |
| REASON J PAUL | director | 23591 0.0044% | $6.43M | 0 | 2 | |
| MILETICH JOSEPH P | Sr VP Rsch & Preclinical Dev | 22500 0.0042% | $6.13M | 0 | 1 | |
| Patton Cynthia M | SVP & CCO | 22097 0.0041% | $6.02M | 0 | 6 | |
| Tross Stuart A | SVP, Human Resources | 21923 0.0041% | $5.97M | 0 | 2 | |
| ECKERT ROBERT | 21184 0.0039% | $5.77M | 0 | 1 | ||
| Dittrich Thomas J.W. | VP, Finance & CAO | 18589 0.0035% | $5.06M | 0 | 5 | |
| SCHAEFFER LEONARD D | director | 16329 0.003% | $4.45M | 0 | 2 | |
| SUGAR RONALD D | director | 15927 0.003% | $4.34M | 0 | 20 | |
| GLUCK FREDERICK W | director | 15748 0.0029% | $4.29M | 1 | 3 | <0.0001% |
| de Carbonnel Francois | director | 15528 0.0029% | $4.23M | 2 | 4 | +16.14% |
| PELHAM JUDITH C | director | 11890 0.0022% | $3.24M | 0 | 9 | |
| COFFMAN VANCE D | director | 10668 0.002% | $2.91M | 1 | 0 | <0.0001% |
| NANULA RICHARD D | Exe VP & CFO | 10000 0.0019% | $2.72M | 0 | 6 | |
| RICHO ANNA | SVP & CCO | 10256 0.0019% | $2.79M | 0 | 12 | |
| Jacks Tyler | director | 8979 0.0017% | $2.45M | 0 | 1 | |
| Such Annette Louise | VP, Finance and CAO | 7183 0.0013% | $1.96M | 0 | 1 | |
| Khosla Rachna | SVP, Business Development | 6630 0.0012% | $1.81M | 0 | 1 | |
| SHARER KEVIN W | director | 5494 0.001% | $1.5M | 0 | 15 | |
| HENDERSON REBECCA M | director | 5549 0.001% | $1.51M | 0 | 2 | |
| Williams R Sanders | 5301 0.001% | $1.44M | 0 | 10 | ||
| Hassan Fred | director | 3582 0.0007% | $975,772.62 | 1 | 0 | <0.0001% |
| HERRINGER FRANK C | director | 2000 0.0004% | $544,820.00 | 2 | 0 | +3.73% |
| DAYEM HASSAN | Sr. V.P. & Chief Info. Officer | 1349 0.0003% | $367,481.09 | 0 | 2 | |
| SCHEHR BARRY D | VP Financial Ops & CAO | 0 0% | $0 | 0 | 3 |
Historical Insider Profitability vs. Competitors
$364,217,072 | 28 | 9.11% | $18.4B | |
$6,077,160 | 24 | 3.21% | $364.68B | |
$1,922,773,492 | 23 | 18.03% | $717.81B | |
$28,542,809 | 19 | 26.41% | $325.05B | |
$23,029,445 | 18 | 9.33% | $95.14B | |
$17,024,470 | 16 | 4.31% | $190.99B | |
$1,995,978 | 16 | -0.53% | $129.8B | |
Amgen Inc. (AMGN) | $3,170,734 | 10 | 3.98% | $146.48B |
$3,933,798 | 8 | 12.50% | $127.5B | |
$252,679 | 2 | 0.47% | $2.35B | |
$69,846 | 1 | -17.98% | $29.27M |
AMGN Institutional Investors: Active Positions
| Increased Positions | 1,393 | +46.05% | 35M | +8.57% |
| Decreased Positions | 1,343 | -44.4% | 26M | -6.4% |
| New Positions | 259 | New | 4M | New |
| Sold Out Positions | 140 | Sold Out | 2M | Sold Out |
| Total Postitions | 3,075 | +1.65% | 418M | +2.18% |
AMGN Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $14.83M | 9.8% | 52.72M | +339,522 | +0.65% | 2024-12-31 |
| Blackrock, Inc. | $12.78M | 8.45% | 45.44M | -206,717 | -0.45% | 2025-03-31 |
| State Street Corp | $8.28M | 5.47% | 29.43M | +117,396 | +0.4% | 2024-12-31 |
| Morgan Stanley | $4.09M | 2.71% | 14.56M | -134,600 | -0.92% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $3.71M | 2.46% | 13.21M | +3M | +25.38% | 2024-12-31 |
| Primecap Management Co/Ca/ | $3.66M | 2.42% | 13M | -1M | -8.79% | 2024-12-31 |
| Geode Capital Management, Llc | $3.51M | 2.32% | 12.48M | +352,143 | +2.9% | 2024-12-31 |
| Capital International Investors | $3.43M | 2.27% | 12.21M | +3M | +40.1% | 2024-12-31 |
| Wells Fargo & Company/Mn | $2.01M | 1.33% | 7.13M | -355,575 | -4.75% | 2024-12-31 |
| Capital World Investors | $1.83M | 1.21% | 6.5M | +6M | +1,291.98% | 2024-12-31 |